In which Musk learns how to put a happy spin on failure from biotech CEOs.
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.
Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.
The verdict on an experimental stem cell therapy developed by Athersys to assist the recovery of stroke patients is coming on April 19.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
As the CEO of a struggling stem-cell therapy company, Hedrick needs to don brightly colored pom-poms just to grab investors' attention.
Investors were treated to a hepatitis C data dump Wednesday morning ahead of a European liver disease meeting later in the month.
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
Plans to seek U.S. approval for the Ocular device, known as OTX-DP are now up in the air.